English  |  正體中文  |  简体中文  |  总笔数 :0  
造访人次 :  51499068    在线人数 :  768
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"jia horng kao"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 496-545 / 1180 (共24页)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
每页显示[10|25|50]项目

机构 日期 题名 作者
臺大學術典藏 2021-09-04T06:11:17Z Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: Pooled analysis of two phase 3 trials Jensen D.M.; Asselah T.; Dieterich D.; Foster G.R.; Sulkowski M.S.; Zeuzem S.; Mantry P.; Yoshida E.M.; Moreno C.; Ouzan D.; Wright M.; Morano L.E.; Buynak R.; Bourli?re M.; Hassanein T.; Nishiguchi S.; JIA-HORNG KAO; Omata M.; Paik S.W.; Wong D.K.; Tam E.; Kaita K.; Victor Feinman S.; Stern J.O.; Scherer J.; Quinson A.-M.; Voss F.; Gallivan J.-P.; B?cher W.O.; Ferenci P.
臺大學術典藏 2021-09-04T06:11:17Z Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection Yang W.-T.; Wu L.-W.; Tseng T.-C.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:17Z Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection Yang S.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:16Z How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? Wang C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:16Z Perspectives on dual hepatitis B and C infection in Taiwan Liu C.-J.; Chen P.-J.; Chen D.-S.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:15Z Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis JIA-HORNG KAO; Jensen D.M.; Manns M.P.; Jacobson I.; Kumada H.; Toyota J.; Heo J.; Yoffe B.; Sievert W.; Bessone F.; Peng C.-Y.; Roberts S.K.; Lee Y.-J.; Bhore R.; Mendez P.; Hughes E.; Noviello S.
臺大學術典藏 2021-09-04T06:11:15Z Management of hepatitis C patients with decompensated liver disease Hsu C.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:15Z Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:14Z A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection JIA-HORNG KAO; Chien R.-N.; Chang T.-T.; Peng C.-Y.; Hu T.-H.; Lo G.-H.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Han L.; Mo H.; Mathias A.; Brainard D.M.; Sheen I.-S.; Hsu Y.-C.; Chu C.-J.; Chuang W.-L.
臺大學術典藏 2021-09-04T06:11:14Z Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:14Z Review article: novel therapies for hepatitis B virus cure – advances and perspectives Lin C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:13Z Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg Wang C.-C.; Tseng K.-C.; Hsieh T.-Y.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:13Z Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy Hsu C.-S.; Hsu S.-J.; Liu W.-L.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:13Z Liver gene expression profiles correlate with virus infection and response to interferon therapy in chronic hepatitis B patients Wu H.-L.; Hsiao T.-H.; Chen P.-J.; Wong S.-H.; JIA-HORNG KAO; Chen D.-S.; Lu J.-Y.; Lu T.-P.; Chen Y.; Chuang E.Y.; Tu H.-C.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:12Z APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Al-Mahtab M.; McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Lau G.K.K.; Sarin S.K.
臺大學術典藏 2021-09-04T06:11:12Z APASL consensus statements and recommendation on treatment of hepatitis C Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Lau G.K.K.; Sarin S.K.
臺大學術典藏 2021-09-04T06:11:11Z All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study JIA-HORNG KAO; Lee Y.-J.; Heo J.; Ahn S.-H.; Lim Y.-S.; Peng C.-Y.; Chang T.-T.; Torbeyns A.; Hughes E.; Bhore R.; Noviello S.
臺大學術典藏 2021-09-04T06:11:10Z Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; JIA-HORNG KAO; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; Chen C.-C.; Fang Y.-J.; Hung H.-W.; Wu C.-Y.; Lin J.-T.
臺大學術典藏 2021-09-04T06:11:10Z Reply Su T.-H.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:10Z Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis JIA-HORNG KAO; Tung S.-Y.; Lee Y.; Thongsawat S.; Tanwandee T.; Sheen I.-S.; Wu J.J.; Li H.; Brennan B.J.; Zhou J.; Le Pogam S.; Najera I.; Thommes J.A.; Hill G.
臺大學術典藏 2021-09-04T06:11:09Z Peginterferon Lambda-1a/ribavirin with daclatasvir or peginterferon alfa-2a/ribavirin with telaprevir for chronic hepatitis c genotype 1b Flisiak R.; Kawazoe S.; Znoyko O.; Assy N.; Gadano A.; JIA-HORNG KAO; Lee K.-S.; Zwirtes R.; Portsmouth S.; Dong Y.; Xu D.; Kumada H.; Srinivasan S.
臺大學術典藏 2021-09-04T06:11:09Z No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection Sulkowski M.S.; Chuang W.-L.; JIA-HORNG KAO; Yang J.C.; Gao B.; Brainard D.M.; Han K.-H.; Gane E.
臺大學術典藏 2021-09-04T06:11:09Z Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C Mah Y.-H.; Liu C.-H.; Chen C.-L.; Tseng T.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:08Z Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus Su T.-H.; Liu C.-J.; Shu P.-Y.; Fu Y.-H.; Chang C.-H.; Jao P.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:08Z Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium
臺大學術典藏 2021-09-04T06:11:07Z Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace Lin C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:07Z Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model JIA-HORNG KAO; Asselah T.; Dou X.-G.; Hamed K.
臺大學術典藏 2021-09-04T06:11:07Z Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway Liu W.-L.; Yang H.-C.; Hsu C.-S.; Wang C.-C.; Wang T.-S.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:06Z NOhep: Toward Global Control of Hepatitis B Virus Infection - An Introduction Liu C.-J.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:06Z High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments Nien H.-C.; Hsu S.-J.; Su T.-H.; Yang P.-J.; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; JIA-HORNG KAO; Yang W.-S.
臺大學術典藏 2021-09-04T06:11:06Z Unmet Needs in Clinical and Basic Hepatitis B Virus Research Su T.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:06Z Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma Hu M.-H.; Chen L.-J.; Chen Y.-L.; Tsai M.-S.; Shiau C.-W.; Chao T.-I.; Liu C.-Y.; JIA-HORNG KAO; Chen K.-F.
臺大學術典藏 2021-09-04T06:11:05Z Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in?chronic hepatitis B patients Su T.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:05Z Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D Kao C.-N.; Su T.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:04Z Benefits of long-term therapy with nucleos(t)ide analogues in treatment-na?ve patients with chronic hepatitis B Wei L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:04Z Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study Blach S.; Zeuzem S.; Manns M.; Altraif I.; Duberg A.-S.; Muljono D.H.; Waked I.; Alavian S.M.; Lee M.-H.; Negro F.; Abaalkhail F.; Abdou A.; Abdulla M.; Abou Rached A.; Aho I.; Akarca U.; Al Ghazzawi I.; Al Kaabi S.; Al Lawati F.; Al Namaani K.; Al Serkal Y.; Al-Busafi S.A.; Al-Dabal L.; Aleman S.; Alghamdi A.S.; Aljumah A.A.; Al-Romaihi H.E.; Andersson M.I.; Arendt V.; Arkkila P.; Assiri A.M.; Baatarkhuu O.; Bane A.; Ben-Ari Z.; Bergin C.; Bessone F.; Bihl F.; Bizri A.R.; Blachier M.; Blasco A.J.; Brandao Mello C.E.; Bruggmann P.; Brunton C.R.; Calinas F.; Chan H.L.Y.; Chaudhry A.; Cheinquer H.; Chen C.-J.; Chien R.-N.; Choi M.S.; Christensen P.B.; Chuang W.-L.; Chulanov V.; Cisneros L.; Clausen M.R.; Cramp M.E.; Craxi A.; Croes E.A.; Dalgard O.; Daruich J.R.; De Ledinghen V.; Dore G.J.; El-Sayed M.H.; Ergor G.; Esmat G.; Estes C.; Falconer K.; Farag E.; Ferraz M.L.G.; Ferreira P.R.; Flisiak R.; Frankova S.; Gamkrelidze I.; Gane E.; Garcia-Samaniego J.; Khan A.G.; Gountas I.; Goldis A.; Gottfredsson M.; Grebely J.; Gschwantler M.; Guimaraes Pessoa M.; Gunter J.; Hajarizadeh B.; Hajelssedig O.; Hamid S.; Hamoudi W.; Hatzakis A.; Himatt S.M.; Hofer H.; Hrstic I.; Hui Y.-T.; Hunyady B.; Idilman R.; Jafri W.; Jahis R.; Janjua N.Z.; Jar?u?ka P.; Jeruma A.; Jonasson J.G.; Kamel Y.; JIA-HORNG KAO; Kaymakoglu S.; Kershenobich D.; Khamis J.; Kim Y.S.; Kondili L.; Koutoubi Z.; Krajden M.; Krarup H.; Lai M.-S.; Laleman W.; Lao W.-C.; Lavanchy D.; Lazaro P.; Leleu H.; Lesi O.; Lesmana L.A.; Li M.; Liakina V.; Lim Y.-S.; Luksic B.; Mahomed A.; Maimets M.; Makara M.; Malu A.O.; Marinho R.T.; Marotta P.; Mauss S.; Memon M.S.; Mendes Correa M.C.; Mendez-Sanchez N.; Merat S.; Metwally A.M.; Mohamed R.; Moreno C.; Mourad F.H.; Mullhaupt B.; Murphy K.; Nde H.; Njouom R.; Nonkovic D.; Norris S.; Obekpa S.; Oguche S.; Olafsson S.; Oltman M.; Omede O.; Omuemu C.; Opare-Sem O.; Ovrehus A.L.H.; Owusu-Ofori S.; Oyunsuren T.S.; Papatheodoridis G.; Pasini K.; Peltekian K.M.; Phillips R.O.; Pimenov N.; Poustchi H.; Prabdial-Sing N.; Qureshi H.; Ramji A.; Razavi-Shearer D.; Razavi-Shearer K.; Redae B.; Reesink H.W.; Ridruejo E.; Robbins S.; Roberts L.R.; Roberts S.K.; Rosenberg W.M.; Roudot-Thoraval F.; Ryder S.D.; Safadi R.; Sagalova O.; Salupere R.; Sanai F.M.; Sanchez Avila J.F.; Saraswat V.; Sarmento-Castro R.; Sarrazin C.; Schmelzer J.D.; Schreter I.; Seguin-Devaux C.; Shah S.R.; Sharara A.I.; Sharma M.; Shevaldin A.; Shiha G.E.; Sievert W.; Sonderup M.; Souliotis K.; Speiciene D.; Sperl J.; Starkel P.; Stauber R.E.; Stedman C.; Struck D.; Su T.-H.; Sypsa V.; Tan S.-S.; Tanaka J.; Thompson A.J.; Tolmane I.; Tomasiewicz K.; Valantinas J.; Van Damme P.; Van Der Meer A.J.; Van Thiel I.; Van Vlierberghe H.; Vince A.; Vogel W.; Wedemeyer H.; Weis N.; Wong V.W.S.; Yaghi C.; Yosry A.; Yuen M.-F.; Yunihastuti E.; Yusuf A.; Zuckerman E.; Razavi H.; The Polaris Observatory HCV Collaborators
臺大學術典藏 2021-09-04T06:11:03Z Surveillance of hepatocellular carcinoma by magnetic resonance imaging with liver-specific contrast Su T.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:03Z Elimination of Hepatitis B: Is It a Mission Possible? Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:03Z De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline Lin Y.-Y.; Hsieh C.-H.; Chen J.-H.; Lu X.; JIA-HORNG KAO; Chen P.-J.; Chen D.-S.; Wang H.-Y.
臺大學術典藏 2021-09-04T06:11:02Z Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants Lin C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:02Z Urgency to treat patients with chronic hepatitis C in Asia JIA-HORNG KAO; Ahn S.H.; Chien R.-N.; Cho M.; Chuang W.-L.; Jeong S.-H.; Liu C.-H.; Paik S.-W.
臺大學術典藏 2021-09-04T06:11:02Z Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir Liu C.-H.; Chen Y.-S.; Wang S.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:01Z Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study Wang C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:01Z Letter: the influence of direct acting agents for hepatitis C, on hepatitis B reactivation Wang C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:01Z HBV markers for HCC prediction: Three heads are better than two? Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:01Z More viral mutants, less HBsAg clearance? One size may not fit all Tseng T.-C.; Yang H.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:00Z An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia Hsu C.S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:00Z Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; Yang T.-H.; JIA-HORNG KAO; Chen C.-C.; Tseng C.-H.; Tai C.-M.; Lin C.-W.; Wu C.-Y.; Lin J.-T.
臺大學術典藏 2021-09-04T06:10:59Z Fibrosis-4 Index Helps Identify HBV Carriers with the Lowest Risk of Hepatocellular Carcinoma Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:10:59Z Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up Chen H.-Y.; Su T.-H.; Tseng T.-C.; Yang W.-T.; Chen T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO; Liu C.-J.

显示项目 496-545 / 1180 (共24页)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
每页显示[10|25|50]项目